Ondansetron is a selective serotonin receptor antagonist used to prevent nausea and vomiting associated with chemotherapy and surgery. It belongs to the class of 5-ht3 receptor blockers that inhibit the action of serotonin in the gastrointestinal tract and the chemoreceptor trigger zone. By binding to 5-ht3 receptors on the intestinal mucosa it reduces the signaling that initiates emesis. The drug also blocks 5-ht3 receptors on vagal afferent fibers decreasing the pathways involved in nausea perception. Ondansetron's active metabolite retains similar receptor affinity and contributes to its prolonged anti-emetic effect. It is absorbed rapidly after oral administration and undergoes hepatic metabolism with a half-life of approximately five to six hours. The medication crosses the blood-brain barrier poorly which limits central nervous system sedation compared to other antiemetics. This targeted peripheral action makes it effective for controlling chemotherapy-induced nausea without significant drowsiness

Ondansetron is a medication that belongs to a class of drugs called serotonin receptor antagonists. It is primarily used to prevent nausea and vomiting caused by chemotherapy, surgery, or radiation therapy. The drug works by blocking serotonin receptors in the intestine and the central nervous system. These receptors are part of the body's signaling pathways that trigger the sensation of nausea. By occupying the receptors, Ondansetron stops the cascade of signals that would normally lead to vomiting. This action helps patients tolerate treatments that often cause gastrointestinal side effects. Its effect is specific to the 5-ht3 receptor subtype, which is most involved in the nausea response. As a result the medication reduces the likelihood of acute and delayed nausea without directly affecting other bodily functions.

Many patients report mild headache, fatigue, or nausea after treatment. Skin irritation can occur at the application site. Some individuals experience temporary changes in taste perception. Mild dizziness is occasionally noted during dosage adjustments. Mild swelling may appear around injection sites if used. Most side effects are short-lived and resolve without intervention.

The most common side effects often include mild headache, nausea, and fatigue. These reactions are usually short lived and resolve on their own. Some individuals may experience temporary dizziness or mild skin irritation. Less frequently, mild digestive discomfort can occur. The occurrence of these effects is generally related to dosage and individual sensitivity. Most people do not experience severe or lasting symptoms. Monitoring how the body responds helps determine if any changes are needed.